Back to search

Article

Multi-omic and functional screening reveal targetable vulnerabilities in<i>TP53</i>mutated multiple myeloma

2024-08-23

Abstract excerpt

<h4>ABSTRACT</h4> Despite development of several effective therapies for multiple myeloma (MM), the prognosis of patients with partial deletion of chromosome 17 (del(17p)) and TP53 aberrations remains poor. By applying comprehensive multi-omics profiling analyses (whole exome and transcriptome sequencing plus proteomics) and functional ex vivo drug screening to samples from 167 patients with MM, we uncovered novel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a3fecab4-ddec-5dfa-978a-b1a186b683f2
DOI
10.1101/2024.08.23.24312359
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multi-omic and functional screening reveal targetable vulnerabilities in<i>TP53</i>mutated multiple myelomaDOI 10.1101/2024.08.23.24312359
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity
Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or Deleted<i>TP53</i>Semantic proximity
Deregulation and Targeting of TP53 Pathway in Multiple MyelomaSemantic proximity
Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.Semantic proximity
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myelomaSemantic proximity
Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity
Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cellsSemantic proximity
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma ModelsSemantic proximity
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.Semantic proximity
Select a neighboring publication to make it the new centre.